The abstract shows that IDH mutations reduce protein enzymatic activity yet paradoxically correlate with improved prognosis. This counterintuitive finding suggests unknown mechanisms by which metabolic dysfunction may actually benefit patients or reflect less aggressive tumor biology. Gap type: unexplained_observation Source paper: IDH1 and IDH2 mutations in gliomas. (2009, N Engl J Med, PMID:19228619)
Landscape Summary: What mechanisms explain how IDH1/IDH2 mutations with reduced enzymatic activity lead to better patient outcomes? is a 0.89 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: partially_addressed.
Colonna, Sevlever, et al. (TREM2 biology)
What mechanisms explain how IDH1/IDH2 mutations with reduced enzymatic activity lead to better patient outcomes? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: